Results 101 to 110 of about 12,173,986 (325)

Conferencias anatomoclinicas: caso No. veintiuno

open access: yesRevista de la Facultad de Medicina, 1955
M. del C. A. 40 años. Ciudad de origen: Zipaquirá. Procedencia Bogotá. Servicio del Profesor Rico. NOTA CLINICA: La paciente ingresa por primera vez al Hospital el 8 de octubre de 1951, por presentar episodios psicomotores diagnosticados inicialmente ...
San Juan de Dios Hospital
doaj  

Barnes Hospital Bulletin [PDF]

open access: yes, 1973
https://digitalcommons.wustl.edu/bjc_barnes_bulletin/1093/thumbnail ...

core   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

Conferencias anatomoclínicas: caso no. veintisiete

open access: yesRevista de la Facultad de Medicina, 1956
Se hace una revisión de un caso clínico presentado en el Hospital San Juan de Dios, Bogotá.
San Juan de Dios Hospital
doaj  

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Conferencias anatomoclínicas: caso no. veinticinco

open access: yesRevista de la Facultad de Medicina, 1956
Se hace una revisión de un caso clínico presentado en el Hospital San Juan de Dios, Bogotá.
San Juan de Dios Hospital
doaj  

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy